OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2013.1141 ol-05-04-1433 Corrigendum Corrigendum 4 2013 18 01 2013 5 4 1433 1433 Copyright © 2013, Spandidos Publications 2013 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.

Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer

YUJI HAYASHI, HIROYUKI TAKEI, SATOSHI NOZU, YOSHIHIRO TOCHIGI, AKIHIRO ICHIKAWA, NAOKI KOBAYASHI, MASAFUMI KUROSUMI, KENICHI INOUE, TAKASHI YOSHIDA, SHIGENORI E. NAGAI, HANAKO OBA, TOSHIO TABEI, JUN HORIGUCHI and IZUMI TAKEYOSHI

Oncology Letters 5: 83–89, 2013; DOI: 10.3892/ol.2012.1004

After the publication of the article, the authors noted that they had made an error regarding certain data in their manuscript. The error relates to the calculations made in Table IV.

On page 88 of our article, in the left-handed column, we identified an erroneous statistical result with respect to the percentages calculated in Table IV. Please see the corrected table below.

Presence or absence of residual DCIS and MRI diagnoses.

Residual DCIS (%)
Response Absence Presence Total (%)
cCR 36 (36.7) 8 (8.2) 44 (44.9)
Residual tumor 30 (30.6) 24 (24.5) 54 (55.1)
Total 66 (67.3) 32 (32.7) 98 (100.0)

P=0.0058. cCR, clinical complete response; DCIS, ductal carcinoma in situ; MRI, magnetic resonance imaging.